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Abstract: Complexes of diazoxide (3-methyl-7-chloro-l,2,4-benzothiadiazine-l,l-dioxide) an anti-
hypertensive and hyperglycemic pharmacological agent with a series of transition- and main-group di-, tri-
and tetravalent metal ions were prepared and characterized by elemental analysis, spectroscopic,
thermogravimetric, magnetic and conductimetric measurements. The complexes were tested as inhibitors of
the enzyme carbonic anhydrase (CA), proving modest activity towards CA II and better inhibition ofCA I.
Introduction
In connection with our interest to develop novel types of inhibitors of the enzyme carbonic
anhydrase (CA, EC 4.2.1.1),
1,2 we reported a large number of coordination compounds of heterocyclic and
aromatic sulfonamides, 2,3 containing a large range of transition and main-group metal ions. Some of these
derivatives showed excellent CA inhibitory properties (for isozymes CA I and CA II, the major red cell
CAs1) and their mechanism of action at molecular level was also rationalized.
4
Ligands used in such studies included heterocyclic sulfonamides with well-known CA inhibitory
5 6 7 prpperties, such as acetazolamide 1; methazolamide 2; ethoxzolamide 3; thienothiopyran sulfonamides
4;
8 (all these are clinically used CA inhibitors ,2) as well as saccharin 5,
9 for which CA inhibitory
properties were discovered recently.
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Acetazolamide was the first non-mercurial diuretic in clinical use,
11,12 and subsequently its
applications were based upon its antiglaucoma,
13 antiepileptic
]4 and antiulcerogenic
15 effects. Together
with the related drugs methazolamide and ethoxzolamide, they were used in clinical medicine for more than
40 years.
11 Derivative 4 was recently introduced in clinical medicine as topical antigllUcoma agents, being
thoroughly effective in lowering elevated eye pressure, without undesired side effects.
Acetazolamide 1 also played a major role in the development of renal physiology and
pharmacology, 1,2 and led to the synthesis of two classes of drugs: the benzothiadiazide ("thiazide"
diuretics) and the high-ceiling diuretics. 11’16 From the first type of such compounds, chlorothiazide (6-
chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide) is a widely used diuretic drug for treating a variety
15,16 of disorders such as edema, congestive heart failure, hypertension, etc.
Among the large number of 1,2,4-benzothiadiazine-l,l-dioxides reported,
16 3-methyl-7-chloro-
1,2,4-benzothiadiazine-l,l-dioxide 6 (diazoxide, abbreviated as HDZO in this work) proved completely
different properties as compared to the structurally related diuretics, such as chlorothiazide and its
congeners (which possess a sulfamoyl group in position 7 and lack the methyl from 3). Thus, diazoxide in
clinical use since the 1960-s is a potent hypotensive drug, its mechanism of action involving the activation
of ATP-sensitive potassium channels, and relaxation ofvascular smooth muscles.
17 By the same mechanism
of action, diazoxide inhibits insulin secretion,
18 and shows potent hyperglycemic properties,
9 which are
useful in the treatment ofvarious forms of hypoglycemia.
19
Although, as seen from the above data, derivatives of type 1-6 possess prominent biological
activities, and are valuable pharmacological aents, used clinically for a long period, excepting for
sulfonamides 15, recently investigated by us,
-ltr the coordination chemistry of benzothiadiazines was not
studied. Thus, a program was initiated in our laboratory to investigate the coordination chemistry of such
and related derivatives, as well as the biological activity of the synthesized complexes. In this paper I report
the preparation, coordination behavior and biological activity data of metal complexes of diazoxide. In
future reports data for complexes of related (diuretic) benzothiadiazine-1,1-dioxides will be presented.
Materials and Methods
FTIR spectra were obtained on thin films ofpure compound, with a Perkin Elmer 1600 instrument,
in the range 200 4000 cm1. Electronic spectra were obtained by the diffuse reflectance technique in MgO
as reference, with a Perkin Elmer Lambda 17 apparatus. Solution electronic spectra were done in ethanol or
methanol with a Cary 3 instrument. Conductimetric measurements were done in DMF solutions, at 25C
(concentrations of 1 mM of complex) with a Fisher conductimeter. Magnetic susceptibility measurements
were done at room temperature by Faraday’s method, using CoHg(NCS)4 as standard. Elemental analyses
were done by combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the
metal ions, and were + 0.4% of the theoretical values. Thermogravimetric measurements were done in air,
at a heating rate of 10C/min., with a Perkin Elmer 3600 thermobalance.
Diazoxide 6 used in the syntheses was from Merck. Metal salts were from Merck, Fluka or Aldrich
and were used without additional purification. Bovine CA II and human CA I were from Sigma Chemical
Co. Inhibitors were assayed by Maren’s micromethod2, in the conditions of the E-I (enzyme-inhibitor)
technique, at 0C in veronal buffer. IC50 values represent the molarity of inhibitor producing a 50%
decrease ofCA specific activity for the CO: hydration reaction.
Synthesis of coordination compounds 8-17
A cold solution of diazoxide sodium salt (NaDZO, 7) was prepared by suspending HDZO in a 2N
NaOH solution, working at 0-5C. Mention should be made that the benzothiadiazinic ring is not very
stable in the presence of bases, being cleaved to orthanilamide derivatives.
16 Still, at room temperature and
in 2N NaOH, diazoxide is cleaved in about 150 hours,
16 so that, presumably, no decomposition occurred
during the experiments reported here, in which complexes were prepared in about 0.5 1 hours. The cold
solution obtained above, was mixed with a methanolic-aqueous solution of metal salts (MCI: or MC13), in
molar ratios of 2:1 and 3:1, respectively, and the obtained reaction mixture was stirred magnetically at room
temperature for 0.5 hours. The obtained precipitates were filtered and air-dried.
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Results and Discussion
Starting from the sodium salt of diazoxide, NaDZO 7, prepared in situ from diazoxide and NaOH
(the pKa of the SONH moiety of diazoxide is 8.5)
21 both transition- as well as main-group metal
complexes were obtained. Generally, cations which led to strong CA inhibitors in complexes with
sulfonamides 1-51-10 were included in the present study, such as Cu(II); Zn(II); Hg(II); Fe(III); V(IV), etc.
The synthesized compounds 8-17 and their elemental analysis data (+ 0.4% of the theoretical values, for
C,H,N, by combustion, and forM by gravimetry) are shown in Table I.
Table I: The prepared diazoxide complexes 8-17, and their elemental analysis data (DZO stands for the
sulfonamide deprotonated species of the ligand).
No. Compound Color Analysis (calc./found,)
%M
a %C
b %H
t %N
b
8 [Co(DZO)(OH)4] violet 9.9/9.5 32.5/32.4 3.3/3.4 9.5/9.2
9 [Ni(DZO)2(OH2)4] smaragd 9.9/9.5 32.5/32.3 3.4/3.3 9.5/9.2
10 [Cu(DZO)2(OH2)4] gray 10.6/10.2 32.3/32.1 3.3/3.1 9.4/9.1
11 [Zn(DZO)2(OH2)2] white 11.7/11.2 34.3/34.2 2.8/2.9 10.0/9.7
12 [Cd(DZO)(OH2)4]] white 17.4/17.0 29.8/29.7 3.1/3.0 8.7/8.5
13 [Hg(DZO)(OH)4] white 27.4/26.8 26.2/26.2 2.7/2.5 7.6/7.6
14 [PDZO)(OH)a].2HO white 26.7/26.3 24.8/24.6 3.1/2.9 7.2/7.1
15 [Fe(DZO)3(OH)3] brown 6.9/6.6 36.0/36.1 3.0/2.8 10.5/10.4
16 [AI(DZO)3(OH)3].6HO white 3.0/2.5 32.8/32.5 4.1/4.0 9.5/9.3
17 [VO(DZO)(OH)].HO gray 8.7/8.5 33.1/32.8 3.1/2.9 9.6/9.5
aBy gravimetry; bBy combustion
The new compounds were further characterized by IR-, and electronic spectroscopy (in solution as
well as by the diffuse reflectance technique); thermogravimetric (TG) analysis, magnetic and conductimetric
measurements. Some of these data are shown in Tables II and III.
Table II: Spectroscopic andTG data for compounds 6-17.
Comp. IR. Spectra
a ,cm’l
v(M-L) v(SO2)s v(SO2)as
UV Spectra b, TG analysis
c
max, nm (lge) T(C) found/calc.
6 1150 1342 215 (3.94); 278 (4.08)
7 1152 1345 215 (3.96); 289 (4.23)
8 341;398 1135 1290 215 (3.97); 289 (4.51) 120-170 12.1/12.2d
9 340;398 1136 1283 215 (3.96); 289 (4.53) 120-170 12.0/12.2d
d 10 310;400 1139 1286 215 (3.97); 289 (4.61) 120-180 11.8/12.1
11 348;400 1137 1280 215 (3.96); 289 (4.38) 120-160 6.3/6.4e
12 350;400 1139 1283 215 (3.96); 289 (4.55) 115-175 11.0/11.2d
13 337;396 1138 1285 215 (3.97); 289 (4.29) 125-185 9.6/9.8d
14 340;398 1134 1283 215 (3.96); 289 (4.37) 105-115 4.5/4.6e
15 335;380 1138 1288 215 (3.96); 289 (4.40) 125-170 6.4/6.7 g
16 330;384 1138 1290 215 (3.97); 289 (4.31) 100-120 12.2/12.3h’i
17 340;399 1139 1287 215 (3.95); 289 (4.62) 100-110 2.8/3.1j&
a FTIR spectra of thin films of pure compound;
b In ethanol;
e Weight loss, % (only the first step, together
with the corresponding temperature range shown), corresponding,to:
d 4HO
e 2H:O;
f Another step
occurs at 120-180C, corresponding t.o 4HO (9,.0/9.3%);
g 3 H:O;
n 6 H20; Another step at 125-170C,
corresponding to 3HO (6.0/6.1%); 1 H:O; another step at 120-160C (6.1/6.2%, corresponding to
2HO).
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In the IR spectra of complexes 8-17, the following modifications were evidenced, as compared to
the IR spectrum of the ligand 6, or its sodium salt 7: (i) important changes in the region 1100-1350 cm
-1
-1’ where the SO2 vibrations appear. Thus, _in ligand 6, the symmetrical vibration appears at 1150 cm
whereas the asymmetrical one at 1342 cm In the sodium salt 7, the corresponding frequencies are only 2-
3 cm
"1 shifted towards higher wavenumbers, but in all complexes 8-17, important shifts towards lower
wavenumbers occur: with 52-62 cm
"1 for the asymmetrical vibrations, and with 11-16 cm
"1 for the
symmetrical one. Besides, this last vibration is splitted in the spectra of all complexes 8-17 (data not
shown), as an extra band at 1160 cm
-1 appears. Mention should be made that a similar behavior was
documented for other SO2 vibrations in complexes of heterocyclic sulfonamides of types 1-5, previously
reported by this and Borras’ groups;
1-10 (ii) the absence of v(NH) vibrations in the spectra of complexes 8-
17 and the sodium salt 7, whereas in diazoxide 6 they appear at 3080 cm"1 (iii) the presence of v(OH)
bands, around 3400 cm-l,in the spectra of the coordination compounds, which are absent in the spectra of
the ligand and its sodium salt(data not shown); (iv) appearance of bands in the region 300-400 cm
"1
attributed to v(M-N) and v(M-O) vibrations, in the spectra of complexes 8-17, which are again absent in the
spectra of 6 and 7; (v) the other bands in the IR spectra of compounds 8-17 (for instance v(C=N) and v
(C=C), in the region 1400-1600 Cm
"1 ) appear at the same wavenumbers as in the ligand 6, probably due to
the fact that the part of the molecule in which they are present is not much affected by interaction with the
metal ions (data not shown).
In the electronic spectra (in solution) of diazoxide 6, two absorption maxims are seen, at 215 and
278 nm, respectively, as for other structurally-related benzothiadiazine-l,l-dioxides possessing a similar
substitution pattern.16e’2 For the sodium salt 7, the first maximum is identical with that of diazoxide 6,
whereas the second one undergoes a bathochromic shift at 289 nm (and a small hyperchromic effect).
2 In
the new complexes 8-17, a similar behavior to that of the sodium salt was evidenced (Table II), as the first
maximum remained unchanged, whereas the second one was bathochromically shifted to 289 nm. Such a
pattern of the electronic spectra proves that in complexes 8-17 it is the diazoxide anion interacting with the
metal ions, similarly with heterocvclic sulfonamides of type 1-5, which generally coordinate metal ions as
deprotonated species, RSO2NH-.
-9
Table III: Diffuse reflectance spectra, magnetic moments and proposed geometries for complexes 8-17.
Complex Electronic spectra (v, cm-1)
a
}teff (BM)
b Geometry
8 25,600; 18,500(sh); 15,630 5.28 octahedral
9 17,000; 12,600 3.43 octahedral
10 16,200 1.88 distorted octahedral
11 c d tetrahedral
12-14, 16 c d octahedral
15 24,600; 20,300; 10,400 5.77 octahedral
17 25,900; 15,500; l l,900(sh) 1.85 square pyramidal
a In MgO as standard material;
d Diamagnetic.
b At room temperature;
e No transitions in this spectral region seen;
Reflectance diffuse (RD) spectra of complexes containing colored metal ions are shown in Table
III, together with magnetic moment data (at room temperature) and the proposed geometries of the
respective metal ions in their complexes with diazoxide. From the above data, it is seen that the Co(II)
complex 8 shows two bands in the RD spectrum, at 25,600 and 15,630 cm
"1 respectively, assigned as the v
3 and v2 transitions, and a shoulder at 18,500 cm-1. The Vl calculated from the Lever tables is 7,260 ,which
leads to a v2/vl ratio in the range of 2.1-2..2, which correlated with a magnetic moment of 5.28 BM at room
temperature, suggests an octahedral geometry for the Co(II) ion.
:3 This is also supported by TG analysis
data (Table II), which proved that the four water molecules are lost in a single step, between 120-170 C,
being coordinated to the metal ion. For the Ni(II) complex 9, two weak transitions were evidenced in the
RD spectrum, at 17,000 and 16,200 cm" attributed to the Vl and v: transitions of Ni(II) in octahedral
surrounding.5’6 This is also supported by the magnetic moment of 3.43 BM.6’:4 The Cu(II) complex 10
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shows a large structureless band centered at 16,200 cm
-1 and a magnetic moment of 1.88 BM, indicating
probably a distorted octahedral geometry of Cu(II).
6 In the last two complexes water is also directly bound
to the metal ions, since by means ofTG analysis it was shown that this is lost in one step, between 120-
180C.
The other metal ions showing an interesting RD spectrum in their complexes with diazoxide are
Fe(III) and V(IV). Thus, the iron derivative 15 is in its predilect geometry octahedral as proved both by
spectral as well as magnetic data (Table III), whereas the V(IV) derivative 17 in SClUare pyramidal
surrounding, as for the related complexes of sulfonamides 1-5, containing these metal ions.
4-7,25
Geometries of other metal ions in the complexes with diazoxide were inferred taking into account
the stoichiometry as well as TG data. Thus, the Zn(II) complex is probably in tetrahedral surrounding, as
only two water molecules are present in its molecule, which are lost again at high temperature, whereas for
Cd(II); Hg(II) and AI(III) complexes, an octahedral geometry of the metal ions is suggested. Some of these
complexes also contain lattice water, which was the first lost during the TG analysis (between 100-120C),
followed by the coordinated water molecules, lost at higher temperatures (Table II).
Conductimetry (data not shown) in DMF solution (1 mM), at room temperature, proved complexes
8-17 as well as ligand 6 to be non-electrolytes, whereas the sodium salt 7 was an 1:1 electrolyte.
From the above data it can be concluded that diazoxide 6 is a monodentate ligand, interacting with
metal ions by means ofthe ionized sulfonamide-type nitrogen atom (N-2) of the benzothiadiazine ring. This
behavior is very similar to that of saccharin 5, which is also a monodentate ligand, complexing metal ions
by means of the ionized nitrogen atom.9’1 The prepared complexes are generally octahedral, probably with
two diazoxide anions coordinated in trans of each other and four water molecules in the equatorial plane
(for the divalent ions, such as Co(II); Ni(II); Cd(II), etc.), or they may possess a different geometry (the
Zn(II) or V(IV) derivatives). The complexes of the trivalem metal ions (AI(III) and Fe(III) ) are again
octahedral, with three diazoxide anions and three water molecules coordinated.
The prepared complexes were tested for their ability to inhibit carbonic anhydrase isozymes CA I
(human) and CA II (bovine), which are the major components of erythrocyte CA (Table IV).
Table IV CA I and II inhibition data, for CO2 hydration, with compounds 1, 5-17, determined by Maren’s
method.
2o For comparison data ofa strong (1) and a weak (5) CA inhibitor are also included.
Compound IC50 (M)
a
CA I CA II
1 0.2
b 0.07
b
5 188 97
6 106 54
8 84 90
9 91 105
10 44 40
11 102 145
12 86 100
13 37 35
14 72 60
15 91 98
16 119 160
17 105 125
a Molarity of inhibitor producing a 50% decrease ofenzyme specific activity for the CO2 hydration reaction,
at 0C;
b From refs.11; eFrom ref.
lO
As seen from the above data, diazoxide is a much weaker CA inhibitor as compared to
acetazolamide 1 (one of the very strong inhibitors), and this is due to the fact that the sulfonamido group is
12 substituted (being; of the type SO2NH-X, not SO2NH2). Generally, it is well documented’ that such a
substitution pattern leads to decreased CA inhibitory properties. Still, saccharin, which possesses the same
moiety as diazoxide, has CA inhibitory properties in the micromolar range,
1 which is also the case with the
last compound. Taking into account that such drugs are used in high enough doses, it might be possible that
even such a weak enzyme inhibitory effect might trigger physiological responses. It is interesting to note on
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the other hand, that the metal complexes prepared in this study are generally weaker inhibitors too, only
some of them being more effective than the lgand, a situation diverse from that of the comolexes of
heterocyclic sulfonamides, which act as very potent CA inhibitors for both isozymes studied here.
r-9 In this
context, tile strongest inhibitors are the Cu(II) and Hg(II) derivatives 10 and 13. Probably these compounds
are the most effective in inhibiting the proton shuttle of these enzymes, by binding to His-64, as proved for
some of their salts by Silverman’s group.
26 It is to mention too, the slightly better CA I inhibition with the
complexes, as compared to CA II, which is a rare case, since sulfonamides have higher affinities to the last
isozyme.
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